How Do Regulatory Bodies Address Off-Target Effects?
Regulatory agencies, such as the FDA and EMA, require comprehensive evaluation of potential off-target effects during the drug approval process. This includes rigorous preclinical testing and analysis of clinical trial data to assess the risk-benefit profile of a compound. Post-marketing surveillance continues to monitor adverse effects, ensuring that any off-target toxicity is swiftly identified and managed.
